By Joe Hoppe

UK-based house builder Persimmon has reported a decrease in its sales rate for 2023, although demand showed improvement in the final quarter and the company's forward sales position has increased.

According to Persimmon's statement on Wednesday, the private average sales rate for the year ending December 31, 2023, declined to 0.58 per outlet per week, compared to 0.69 in 2022. However, the sales rate for the fourth quarter improved to 0.41 from 0.28.

Despite a decrease in the volume of new home legal completions to 9,922 from 14,868 compared to the previous year, Persimmon exceeded its guidance of 9,500 homes. The average selling price of new homes also saw an increase to £255,750 ($325,083) from £248,616 year-on-year, while private average selling prices rose to £285,770 from £272,200.

The company reported a total forward sales value of £1.06 billion as of December 31, 2023, compared to £1.04 billion in the previous year.

Looking ahead, Persimmon anticipates highly uncertain market conditions for 2024. However, it notes that mortgage rates are starting to ease and building costs are gradually moderating. The company remains positive about the long-term demand outlook for new homes.

"We have seen strong customer response to Persimmon's offerings throughout the year, with relatively robust sales rates. To position the business for sustainable growth when conditions improve, we have effectively managed costs while making strategic investments," commented Chief Executive Dean Finch.

Loose Parts Found on Boeing 737 MAX 9 Jets

Bang & Olufsen Affirms Full-Year Guidance, Expects Lower Revenue in Asia-Pacific Region

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Siemens Shares Rise on Strong Q4 Results
News

Siemens Shares Rise on Strong Q4 Results

Siemens' Q4 revenue and orders surpass estimates, with strong free cash flow. Positive outlook despite global demand slu...

Nemetschek Reports Decrease in Q2 Net Profit
News

Nemetschek Reports Decrease in Q2 Net Profit

Shares of Nemetschek dropped after reporting lower net profit in Q2 due to transition to subscription model. Revenue inc...

Positive Results and Completion of Phase 3 Trial for Brilaroxazine in Schizophrenia Patients
News

Positive Results and Completion of Phase 3 Trial for Brilaroxazine in Schizophrenia Patients

Reviva Pharmaceuticals sees stock surge after positive results and completion of Phase 3 trial for Brilaroxazine in trea...

Bitcoin Decline Raises Concerns for Risk Sentiment
News

Bitcoin Decline Raises Concerns for Risk Sentiment

Bitcoin's recent decline below key technical levels may indicate further drops in the stock market, highlighting its rol...